Valuation: Cipher Pharmaceuticals Inc

Market Cap 339M 238M 214M 199M 181M 22.67B 342M 2.39B 932M 11.79B 895M 875M 37.71B P/E 2026 *
11.9x
P/E 2027 * 11x
Enterprise Value 339M 238M 214M 199M 181M 22.67B 342M 2.39B 932M 11.79B 895M 875M 37.71B EV / Sales 2026 *
4.79x
EV / Sales 2027 * 4.17x
Free-Float
57.46%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer - 2019-07-28
Director of Finance/CFO - 2024-08-09
Director of Finance/CFO - 2022-08-14
Director TitleAgeSince
Chairman - 2019-06-11
Director/Board Member 78 2023-06-20
Director/Board Member - 2023-06-20
Change 5-day change 1-year change 3-year change Capi.($)
-22.72%-5.31% - - 242M
+3.62%+4.43%+47.52%+98.41% 1,040B
+2.13%-0.34%+33.01%+61.88% 599B
+3.32%+6.30%+23.09%+91.59% 485B
+3.80%+3.83%+71.96%+41.69% 350B
+3.09%+6.03%+27.85%+45.42% 345B
+2.82%+4.68%+17.38%+40.15% 272B
+3.40%+2.86%-3.33%+12.08% 244B
+3.21%+5.84%+45.73%+49.99% 223B
+3.80%+6.45%+29.89%+97.73% 183B
Average -1.08%+2.38%+32.57%+59.88% 415.87B
Weighted average by Cap. +0.91%+2.31%+36.02%+68.68%

Financials

2026 *2027 *
Net sales 70.85M 49.75M 44.6M 41.53M 37.73M 4.73B 71.4M 499M 195M 2.46B 187M 183M 7.87B 81.35M 57.13M 51.21M 47.68M 43.32M 5.44B 81.99M 573M 223M 2.83B 215M 210M 9.04B
Net income 27.7M 19.45M 17.44M 16.23M 14.75M 1.85B 27.91M 195M 76.09M 963M 73.05M 71.47M 3.08B 31.76M 22.3M 19.99M 18.62M 16.91M 2.12B 32.01M 224M 87.25M 1.1B 83.77M 81.95M 3.53B
Net Debt - -
Logo Cipher Pharmaceuticals Inc
Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products, manages the required clinical development and regulatory approval process, and markets those products either directly or indirectly in Canada, the United States and South America. The Company's product categories include dermatology, hospital acute care, out‑licensed, and specialty medicine. Its dermatology products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Absorica (isotretinoin) is an oral retinoid. Durela, its specialty medicine, is an opioid analgesic indicated for the management of moderate to moderately severe pain in adults who require continuous treatment for several days or more. Its pipeline products include Piclidenoson CF-101, MOB-015 and DTR-001.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Cipher Pharmaceuticals Inc